utilized CXCR4 inhibitor AMD3100 for glioma immunotherapy, showing a highly specific targeting the glioblastoma.[27] In accordance with the aforementioned studies, our results suggest that CXCR4 might represent a promising target for molecular imaging in TNBC. Here, CXCR4 is linked to glioblastoma.